EUVIMEDEUVIMED entdecken
Crossref

From operable to systemic: The role of surgery in the era of immunotherapy?

Velibor Simetić, Mirko Stanetić, Ljiljana Tadić-Latinović, Mirko Turić, Slavica Marić, Radovan Jurić

Respiratio · 2026 · 16 (1-2) · 126-135

DOI: 10.5937/respira2602126s ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respiratio, 2026. Verfasst von Velibor Simetić und 5 weiteren Autor:innen. Die Arbeit nennt 43 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The development of immunotherapy and advanced radiotherapy techniques has significantly changed the treatment paradigm for non-small cell lung cancer (NSCLC). The traditional role of surgery as the primary treatment modality in early-stage disease is now being redefined within a multimodal approach. The aim: Analyses the contemporary role of surgery in the era of immunotherapy, with a particular focus on perioperative strategies, integration of radiotherapy, and the importance of biomarkers in patient selection.

Methods

A review of current literature and key clinical trials investigating neoadjuvant and perioperative immunotherapy, including CheckMate 816 and KEYNOTE-671, with an analysis of surgical outcomes and pathological response.

Results

Perioperative immunotherapy leads to a significant increase in pathological complete response (pCR) and major pathological response (MPR), along with improved event-free survival. At the same time, stereotactic body radiotherapy (SBRT) and radioimmunotherapy expand therapeutic options, particularly in inoperable and oligometastatic patients. However, neoadjuvant therapy introduces new surgical challenges, including fibrosis, altered anatomical planes, and an increased risk of complications. Biomarkers such as PD-L1 expression and circulating tumor DNA (ctDNA) are becoming essential tools for therapy personalization.

Conclusion

Surgery remains a key component in the treatment of NSCLC, but within a selective and individualized multimodal approach. The integration of immunotherapy, radiotherapy, and biomarker-driven strategies is redefining the indications and timing of surgical treatment. The future lies in adaptive therapeutic models based on tumor biology and multidisciplinary decision-making.

Zitieren

APA

Simetić, V., Stanetić, M., Tadić-Latinović, L., Turić, M., Marić, S., & Jurić, R. (2026). From operable to systemic: The role of surgery in the era of immunotherapy?. Respiratio, 16(1-2), 126-135. https://doi.org/10.5937/respira2602126s

Vancouver

Simetić V, Stanetić M, Tadić-Latinović L, Turić M, Marić S, Jurić R. From operable to systemic: The role of surgery in the era of immunotherapy?. Respiratio. 2026;16(1-2):126-135. doi:10.5937/respira2602126s

BibTeX
@article{Simeti2026,
  author = {Simetić, Velibor and Stanetić, Mirko and Tadić-Latinović, Ljiljana and Turić, Mirko and Marić, Slavica and Jurić, Radovan},
  title = {From operable to systemic: The role of surgery in the era of immunotherapy?},
  journal = {Respiratio},
  year = {2026},
  volume = {16},
  number = {1-2},
  pages = {126--135},
  doi = {10.5937/respira2602126s}
}
Kostenlos starten →